Q 1. Tell us about your journey as a pharma entrepreneur and what made you venture into pharma and stay on in pharma? My journey started with two good decisions, one- to be a Medical Representative (MR) in Mumbai, which built a strong foundation and the other, to join Helios, a new pharma company, which was like a baptism of fire. Together, they molded me well. I was promoted as a Front Line Manager (FLM) within a year. And after spending four excellent years in Helios, I joined Group Pharma as Product Manager (PM) and ever since, it’s been an exciting learning experience. I was exposed to Pharma very early in life as my dad was in J L Morison, as part of the promoter-team of Warren Pharma. At home, I was the designated telephone operator and order processing clerk. Those were the days of trunk-calls - calling managers and distributors to note down orders. Hence, I was exposed to the excitement of targets, achievements, deficits and campaigns very early in my life. The idea of ‘work-life balance’ was not in vogue. One would look to their parents who worked long hours with pride making it something you wanted to emulate. Things have changed a lot but I would not trade the decision I made, to get into and stay in Pharma.

BrandStorm & FFE

A peek into BrandStorm and FFE 2015 in Pictures and Videos

Key Challenges Facing Indian Pharma

With the Second Wave hitting India, customers (patients and physicians) will continue to socially distance themselves in the foreseeable future. Pharma must use the field force for reach and relationship and digital for frequency and personalised content for better customer experience. The pandemic has made doctors adopt Telehealth in a substantial way to shore up their revenues and this will continue to be one of their channels to engage patients. Telehealth along with EMR/EHR, digital therapeutics and wearables is enabling doctors to better care for their patients. There are many ways in which pharma can support the digital evolution of doctors.

The Pharma Professional’s Guide

Brand Building Special Issue with articles on personal branding, brand differentiation and avoiding brand arrogance

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

Fostering Thought leadership in Healthcare

Top 25 Indian Pharma Companies by Revenues in 2024

India pharma is crucial for global healthcare, providing affordable...

Top 10 Indian Pharma – 2025

India's top 10 pharma companies by market capitalization, offering insights into...

Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025

1. Market Overview The oncology sector remains the most dominant...

FLUX – Indian Pharma in the Post VUCA World

Introduction For decades, leaders and organizations have relied on the...

Marketing

Fostering Thought leadership in Healthcare

Top 25 Indian Pharma Companies by Revenues in 2024

India pharma is crucial for global healthcare, providing affordable...

Top 10 Indian Pharma – 2025

India's top 10 pharma companies by market capitalization, offering insights into...

Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025

1. Market Overview The oncology sector remains the most dominant...

FLUX – Indian Pharma in the Post VUCA World

Introduction For decades, leaders and organizations have relied on the...

Policies/Sales

Fostering Thought leadership in Healthcare

Top 25 Indian Pharma Companies by Revenues in 2024

India pharma is crucial for global healthcare, providing affordable...

Top 10 Indian Pharma – 2025

India's top 10 pharma companies by market capitalization, offering insights into...

Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025

1. Market Overview The oncology sector remains the most dominant...

FLUX – Indian Pharma in the Post VUCA World

Introduction For decades, leaders and organizations have relied on the...

Strategy

Fostering Thought leadership in Healthcare

Top 25 Indian Pharma Companies by Revenues in 2024

India pharma is crucial for global healthcare, providing affordable...

Top 10 Indian Pharma – 2025

India's top 10 pharma companies by market capitalization, offering insights into...

Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025

1. Market Overview The oncology sector remains the most dominant...

FLUX – Indian Pharma in the Post VUCA World

Introduction For decades, leaders and organizations have relied on the...

Thought Leadership
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

Medical Reps will Remain – What will be their Future Role?

There was a phase when the industry feared that digital would eventually replace the medical sales representative but it appears that digital engagements work best when facilitated by an affable and knowledgeable person, who can personalize the information, and the conversation, to the doctor. In pharma, there’s no substituting face-to-face dialogue it seems. And why should it? “Rather than digital replacing a person in pharma, the need of the hour is digitalizing the approach of person. The person and the technology are HERE TO STAY”, says Archis Joshi, Commercial Head at Dr. Reddy’s. The sales role is getting tougher. Medical information, at one point pharma’s greatest value, is today much more freely available than it used to be. In the Indian market which is dominated by generic medicines lacking differentiation, simply informing doctors about the product, isn’t a viable prospect any more when it comes to piquing their interest. “Why are brands that have been around for some time still unable to cross the marketing funnel and are still stuck at either the ‘awareness’ or the ‘interest’ stages, and unable to move towards the ‘purchase’ or ‘recommendation’ stages?” wonders Mehul Shukla, Director, Marketing Excellence at Cipla.